ACM 005
Alternative Names: ACM-005; ACM-005++; ACM-CpGLatest Information Update: 04 Apr 2025
At a glance
- Originator ACM Biosciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; Toll-like receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Jan 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (IM) (NCT06587295)
- 01 Oct 2024 National Cancer Centre and ACM Biolabs plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease, Second line therapy or greater) in Singapore in November 2024 (NCT06587295)
- 23 Jul 2024 ACM Biolabs plans a phase I trial for Cancer in Q3 2024 (ACM Biolabs, July 2024)